NovoRapid is a medication containing insulin aspart at a concentration of 100 international units per milliliter of solution in a cartridge intended for subcutaneous injection using an insulin pen. Insulin aspart is a human insulin analogue characterized by rapid absorption and a short onset of action, making it suitable for pre-meal injection to control postprandial hyperglycemia in patients with type 1 and type 2 diabetes.
What are the ingredients of NovoRapid?
NovoRapid solution for injection contains the following active ingredient:
Insulin aspart: 100 international units per milliliter.
In addition, the solution contains inactive ingredients such as water, hydrochloric acid or sodium hydroxide to adjust the pH, and sodium chloride and phenol as a preservative.
Indications for Use
NovoRapid solution for injection is used to treat diabetes in adults and children 2 years of age and older. This includes:
Type 1 diabetes (where the body does not produce any insulin).
Type 2 diabetes (where the body does not produce enough insulin or cannot use it effectively).
NovoRapid is used to control blood sugar levels after meals. It may also be used as part of a basal insulin bolus regimen.
What is the dosage of NovoRapid?
The dosage of NovoRapid is determined by the doctor based on the patient's individual needs, blood sugar levels, eating pattern, and level of physical activity.
NovoRapid is usually injected subcutaneously just before meals (within 0-15 minutes before starting to eat).
Type 1 diabetes patients may usually require NovoRapid® injections several times a day in addition to long-acting insulin.
Type 2 diabetes patients may require NovoRapid® alone or in combination with other blood sugar-lowering medications, including long-acting insulin.
Patients must learn the correct injection technique and use the insulin pen and needles. The injection site must be changed each time to avoid skin irritation.